List view / Grid view
3 November 2015 | By Black Swan Analysis
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley...
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
22 October 2015 | By Victoria White
Under the terms of the expanded agreement, AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations across the companies’ portfolios...
16 October 2015 | By Victoria White
Scientists investigating whether the malaria drug artesunate could have a significant impact on colorectal cancer have launched a crowdfunding project to fund their work...
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
2 October 2015 | By Victoria White
Merck and DNAtrix will evaluate the efficacy and safety of DNX-2401 in combination with Keytruda in a Phase 2 study...
29 September 2015 | By Victoria White
Advanced targeted therapies now account for 60% of the drugs under development for colorectal cancer...
28 September 2015 | By Victoria White
The results of the study, involving nearly 14,000 patients, may lead to new insights regarding the use of aspirin in gastrointestinal cancer...
28 September 2015 | By Victoria White
While VS-6063 had a generally well tolerated safety profile, there was not a sufficient level of efficacy to warrant continuation of the study...
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
18 August 2015 | By Victoria White
An international study of people with a family history of cancer has shown that a regular dose of aspirin reduces the long-term risk of the disease...
30 July 2015 | By Victoria White
Kyowa Hakko Kirin and Bristol-Myers Squibb are to conduct a Phase 1/2 combination study with mogamulizumab and Opdivo in advanced solid tumours...
30 July 2015 | By Victoria White
Clinical trial results demonstrate that PLX3397 induced prolonged tumour regressions in most patients with tenosynovial giant cell tumour (TGCT)...
13 July 2015 | By Victoria White
In the Phase II IMvigor 210 study, Roche’s atezolizumab shrank tumours in people with locally advanced or metastatic urothelial bladder cancer (UBC)...
10 July 2015 | By Victoria White
Janssen-Cilag International announced today that the European Commission (EC) has approved Imbruvica® (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM).
